Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STS-001 intravenous sodium thiosulfate in primary Raynaud's phenomenon
2023-509432-25-00Phase 2Completed
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sodium thiosulfate in Raynaud disease, sponsored by University Medical Center Groningen. Primary endpoints: Cooling and rewarming plethysmography response and Peripheral blood perfusion by thermography. Started Oct 2025; status: completed.
02
Drugs
sodium thiosulfate
03
Conditions
Raynaud disease
Beyond the preview
Go deeper on 2023-509432-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509432-25-00.